STAAR Surgical Company (STAA) AI Stock Analysis

STAAR Surgical Company, based in Lake Forest, California, develops, manufactures, and markets implantable lenses and delivery systems for ophthalmic surgery. The company provides solutions for visual disorders like myopia, hyperopia, astigmatism, and presbyopia through its Visian implantable Collamer lens (ICL) product family, as well as Hyperopic ICLs. For cataract procedures, it provides preloaded silicone intraocular lenses, injector systems, and related instruments. Founded in 1982, STAAR markets directly in countries including the United States, Japan, and Germany, while utilizing distributor networks in regions such as China, Korea, and India.

STAAR Surgical generated revenue of $230.5M in FY2021, which grew to $284.4M in FY2022 and peaked at $322.4M in FY2023. Revenue then declined 2.6% to $313.9M in FY2024 and fell 23.7% to $239.4M in FY2025. Over the five years from FY2020 to FY2025, revenue grew at a CAGR of 7.9%. Operating margin dropped from 14.5% in FY2021 to -19.2% in FY2025, while net income shifted from $27.5M to -$80.4M. For the trailing twelve months ended June 30, 2026, revenue was $339.6M with a profit margin of 1.1%. In the quarter ended June 30, 2026, revenue increased 111.0% year-over-year, while quarterly earnings declined 10.5%.

As of June 30, 2026, STAAR Surgical held $181.5M in cash and short-term investments against total debt of $35.9M, resulting in net cash of $145.5M. Liquidity remains supported by a current ratio of 4.66 and a low debt-to-equity ratio of 0.10. Shareholders' equity was $365.4M out of $475.2M in total assets. During FY2025, operating cash flow was -$34.2M and free cash flow was -$40.0M. The company deployed cash toward capital expenditures of $5.8M and share buybacks of $6.5M in FY2025.

STAAR Surgical trades at a trailing P/E of 265.9x, compared to 24.6x for the median of its US-listed Healthcare peers. Its forward P/E is 62.5x versus the peer median of 17.3x, and its EV-to-EBITDA stands at 42.8x compared to the peer median of 12.0x. However, its price-to-sales multiple of 3.1x sits below the peer median of 4.1x. Over the past year, the stock fell 12.3%, while the S&P 500 SPY returned 16.8%. Over five years, the stock declined 81.5% compared to an 83.0% gain for the benchmark.

Of the 11 analyst ratings, 4 are Strong Buy, 6 are Hold, and 1 is Strong Sell. The mean price target is $28.00, representing 31.6% upside from the last close of $21.27. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $334.3M and EPS of $0.84, reflecting expected EPS growth of 604.6%. For the next fiscal year, 7 analysts project revenue of $360.6M and EPS of $1.11. The company beat EPS estimates in 3 of the last 4 quarters, with the next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of STAAR Surgical Company (STAA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: STAA income statement, STAA balance sheet, STAA key metrics, STAA analyst forecast, STAA chart. See the STAA stock overview for the latest quote and news.